Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cell Cycle

• Publication date

  2012-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.11.6.19611PMID 22370480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The expanding relevance of nuclear mTOR in carcinogenesis

  2011cited by this paper
• Cytotoxic and immune‐sensitizing properties of nitric oxide‐modified saquinavir in iNOS‐positive human melanoma cells

  2011cited by this paper
• High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

  2011cited by this paper
• In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

  2011cited by this paper
• The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells.

  2011cited by this paper
• Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro

  2011cited by this paper
• Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

  2011cited by this paper
• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

  2011cited by this paper
• The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.

  2011cited by this paper
• Inhibition of SREBP1 sensitizes cells to death ligands

  2011cited by this paper
• Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells

  2010cited by this paper
• The antitumor properties of a nontoxic, nitric oxide–modified version of saquinavir are independent of Akt

  2009cited by this paper
• Tyrosine phosphorylation and CD95: A FAScinating switch

  2009cited by this paper
• TRAIL as a target in anti-cancer therapy.

  2009cited by this paper
• Anti-HIV drugs for cancer therapeutics: back to the future?

  2009cited by this paper
• Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

  2008influential reference
• FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells

  2008cited by this paper
• Targeting prostate cancer based on signal transduction and cell cycle pathways

  2008cited by this paper
• TRAIL death receptors as tumor suppressors and drug targets

  2008cited by this paper
• TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

  2008cited by this paper
• Targeting death-inducing receptors in cancer therapy

  2007influential reference
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• SAHA‐sensitized prostate cancer cells to TNFα‐related apoptosis‐inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis

  2006cited by this paper
• Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme

  2006cited by this paper
• mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells

  2005cited by this paper
• Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein.

  2005cited by this paper
• Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines*

  2004cited by this paper
• Pretreatment of indole‐3‐carbinol augments TRAIL‐induced apoptosis in a prostate cancer cell line, LNCaP

  2003cited by this paper
• Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

  2003influential reference
• Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis*

  2001influential reference
• Functional Characterization of the X-Linked Inhibitor of Apoptosis (XIAP) Internal Ribosome Entry Site Element: Role of La Autoantigen in XIAP Translation

  2000cited by this paper
• Inhibition of Death Receptor-mediated Gene Induction by a Cycloheximide-sensitive Factor Occurs at the Level of or Upstream of Fas-associated Death Domain Protein (FADD)*

  2000cited by this paper
• Apoptosis control by death and decoy receptors.

  1999cited by this paper
• The Role of c-FLIP in Modulation of CD95-induced Apoptosis*

  1999cited by this paper
• FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation.

  1998cited by this paper
• Two CD95 (APO‐1/Fas) signaling pathways

  1998cited by this paper
• HIV-1 protease inhibitors.

  1997cited by this paper
• FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC)

  1997cited by this paper
• HIV-1 protease inhibitors. A review for clinicians.

  1997cited by this paper
• The modular phosphorylation and activation of p70s6k

  1997cited by this paper
• HIV-1 protease inhibitors. A review for clinicians.

  1997cited by this paper
• Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k

  1997cited by this paper
• Vertebrate mRNAs with a 5'-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element

  1994cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Can Compounds of Natural Origin Be Important in Chemoprevention? Anticancer Properties of Quercetin, Resveratrol, and Curcumin—A Comprehensive Review

  2024cites this paper
• Carborane-Based ABCG2-Inhibitors Sensitize ABC-(Over)Expressing Cancer Cell Lines for Doxorubicin and Cisplatin

  2023cites this paper
• Apoptotic Effect of Gallic Acid via Regulation of p-p38 and ER Stress in PANC-1 and MIA PaCa-2 Cells Pancreatic Cancer Cells

  2023cites this paper
• The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors

  2020cites this paper
• Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo

  2019cites this paper
• Senescence as a main mechanism of Ritonavir and Ritonavir‐NO action against melanoma

  2019cites this paper
• Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells

  2018cites this paper
• HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives?

  2017cites this paper
• Effects of NO‐Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

  2015cites this paper
• The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K.

  2015cites this paper
• Saquinavir Induced Suicidal Death of Human Erythrocytes

  2015cites this paper
• Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis.

  2013cites this paper
• No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI NA DOKSORUBICIN

  2013cites this paper
• Advances in Targeting Signal Transduction Pathways

  2012cites this paper
• Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells

  2012cites this paper